Coherus Biosciences Inc [NASDAQ: CHRS] traded at a high on Thursday, posting a 4.31 gain after which it closed the day’ session at $0.95.
The results of the trading session contributed to over 3475686 shares changing hands. Over the past one week, the price volatility of Coherus Biosciences Inc stands at 7.98% while the volatility over the past one month is 9.35%.
The market cap for CHRS stock reached $109.68 million, with 115.89 million shares outstanding and 111.28 million shares in the current float. Compared to the average trading volume of 1.99M shares, CHRS reached a trading volume of 3475686 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Coherus Biosciences Inc [CHRS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CHRS shares is $6.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CHRS stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Coherus Biosciences Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 16, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on November 17, 2023, representing the official price target for Coherus Biosciences Inc stock.
The Average True Range (ATR) for Coherus Biosciences Inc is set at 0.09, with the Price to Sales ratio for CHRS stock in the period of the last 12 months amounting to 0.41.
How has CHRS stock performed recently?
Coherus Biosciences Inc [CHRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.27. With this latest performance, CHRS shares dropped by -13.96% in over the last four-week period, additionally sinking by -9.00% over the last 6 months – not to mention a drop of -57.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CHRS stock in for the last two-week period is set at 40.94, with the RSI for the last a single of trading hit 42.42, and the three-weeks RSI is set at 41.55 for Coherus Biosciences Inc [CHRS]. The present Moving Average for the last 50 days of trading for this stock 1.1605, while it was recorded at 0.9154 for the last single week of trading, and 1.2733 for the last 200 days.
Coherus Biosciences Inc [CHRS]: Deeper insight into the fundamentals
Coherus Biosciences Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.41 and a Current Ratio set at 2.06.
Insider trade positions for Coherus Biosciences Inc [CHRS]
There are presently around $57.57%, or 58.36%% of CHRS stock, in the hands of institutional investors. The top three institutional holders of CHRS stocks are: BLACKROCK INC. with ownership of 11.75 million shares, which is approximately 10.4236%. VANGUARD GROUP INC, holding 10.6 million shares of the stock with an approximate value of $$18.34 million in CHRS stocks shares; and VANGUARD GROUP INC, currently with $$17.99 million in CHRS stock with ownership which is approximately 9.0577%.
